FDA Approves Novel Sickle Cell Disease Treatment

December 3, 2019

FDA Approves Novel Sickle Cell Disease Treatment

The FDA granted accelerated approval to Oxbryta (voxelotor), a novel inhibitor of deoxygenated sickle hemoglobin polymerization, the central abnormality in patients with sickle cell disease.The Accelerated Approval pathway enables the FDA to approve drugs for serious conditions based on results showing it is likely to provide clinical benefits to patients. Yourway has extensive experience expediting clinical trials to take advantage of fast-tracked approval pathways.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

GCSG 2026 US Conference

April 27-29, 2026
San Diego, CA

Schedule a Meeting

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Schedule a Meeting

Media

Articles

Maintaining Temperature Integrity in Direct-to-Patient Clinical Trials

Open chat

Hello! How can I help you?